Annuity Payment Model For Cures May Get Test Drive In Massachusetts

19 Feb 2019

First-ever implementation of often-discussed reimbursement approach for high-cost drugs would involve group of commercial payers to address “portability” issue and may start with Novartis’ Zolgensma.

Commercial payers in Massachusetts are in discussions with Novartis AG subsidiary AveXis Inc. to pilot an annuity payment model for the company’s upcoming gene therapy for spinal muscular atrophy, Zolgensma (onasemnogene abeparvovec).

Zolgensma would be the next gene therapy to reach the market if it is approved, as expected, for type 1...